CYTK earnings date and last-quarter result: last quarter beat, P/E -12.03. Updated 2026-07-23.
Cytokinetics (CYTK) Research Hub
Cytokinetics (CYTK) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 60.73 USD (-0.82%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -12.03, market cap 10.40B. This hub links to the full technical, earnings and options research available for CYTK.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 60.73 USD (-0.82%) |
| 52-week range | 59.79 USD – 88.31 USD |
| Trend regime | Range |
| 14-day RSI | 47.6 (Neutral) |
| Trailing P/E | -12.03 |
| Market cap | 10.40B |
| Dividend yield | 0.00% |
Available research for CYTK
Covered Call on CYTK: how it works, illustrative setup around the real 60.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CYTK: how it works, illustrative setup around the real 60.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CYTK: how it works, illustrative setup around the real 60.73 USD price, max profit/loss, breakeven and when to use it. Educational.
CYTK technical analysis: range, last 60.73 USD, RSI 47.6, 52w range 59.79 USD–88.31 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CYTK in?
Cytokinetics (CYTK) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CYTK in an uptrend or downtrend?
As of 2026-10-26, CYTK is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CYTK's trailing P/E ratio?
CYTK's trailing P/E is -12.03, with a market cap of 10.40B. See the earnings research page for full valuation detail.